Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals.

Search or browse research publications by year, research area, publication type or keyword.

Clear filter

Publication Details

Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial

Zhang J, Kong W, Hu P, Jonker D, Moore M, Ringash J, Shapiro J, Zalcberg J, Simes J, Tu D, O'Callaghan CJ, Liu G, Xu W

(2023), CANCER MEDICINE, 12(5), 6117-28

DOI: 10.1002/cam4.5341

A capability framework to inform the fundamental requirements for clinical trial unit development, growth and long term success in outer metropolitan and rural areas

Woollett, A., Duncan, J., Voskoboynik, M., Shackleton, M., Dooley, M., Blum, R., McPhee, N., Wright, T., Wong, Z. W., Dixon, J., & Jane, S. M

(2023), Contemporary clinical trials communications, 32, 101072

DOI: 10.1016/j.conctc.2023.101072

Immune-related adverse events secondary to immunotherapy in oncology

Yeoh, Hui-Ling; Freilich, Karen Belinda; Voskoboynik, Mark; Moore, Maggie; Andrews, Miles Cameron Gregory; Shackleton, Mark; Haydon, Andrew Mark Meurisse

(2023), Australian Journal of General Practice, 52(6), 378-385

DOI: 10.31128/AJGP-04-22-6408

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV

(2023), Journal of Clinical Oncology, 41(3), 517-27

DOI: 10.1200/JCO.22.00533

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ

(2023), European Journal of Cancer, 178, 162-70

DOI: 10.1016/j.ejca.2022.10.022

Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma

Edwards JM, Andrews MC, Burridge H, Smith R, Owens C, Edinger M, Pilkington K, Desfrancois J, Shackleton M, Senthi S, van Zelm MC

(2023), Clinical & Translational Immunology, 12(9), e1466

DOI: 10.1002/cti2.1466

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B

(2023), JOURNAL OF THORACIC ONCOLOGY, 18(2), 181-93

DOI: 10.1016/j.jtho.2022.10.003

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H

(2023), Journal of Clinical Oncology, 41(3), 528-40

DOI: 10.1200/JCO.22.00343

Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes

Behar Harpaz S, Weber MF, Wade S, Ngo PJ, Vaneckova P, Sarich PEA, Cressman S, Tammemagi MC, Fong K, Marshall H, McWilliams A, Zalcberg JR, Caruana M, Canfell K

(2023), British Journal of Cancer, 128(1), 91-101

DOI: 10.1038/s41416-022-02026-8

The role of surveillance imaging for resected high-risk melanoma

Yan MK, Adler NR, Wolfe R, Pan Y, Chamberlain A, Kelly J, Yap K, Voskoboynik M, Haydon A, Shackleton M, Mar VJ

(2023), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 19(4), 566-73

DOI: 10.1111/ajco.13913

Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study

Wang C, Zoungas S, Yan M, Wolfe R, Haydon A, Shackleton M, Voskoboynik M, Moore M, Andrews MC, Nicholls SJ, Mar V

(2023), CARDIO-ONCOLOGY, 8(1), 23

DOI: 10.1186/s40959-022-00149-8

Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

Maharaj AD, Lubel J, Lam E, Clark PJ, Duncan O, George J, Jeffrey GP, Lipton L, Liu H, McCaughan G, Neo EL, Philip J, Strasser SI, Stuart K, Thompson A, Tibballs J, Tu T, Wallace MC, Wigg A, Wood M, Zekry A, Greenhill E, Ioannou LJ, Ahlenstiel G, Bowers K, Clarke SJ, Dev A, Fink M, Goodwin M, Karapetis CS, Levy MT, Muller K, O'Beirne J, Pryor D, Seow J, Shackel N, Tallis C, Butler N, Olynyk JK, Reed-Cox K, Zalcberg JR, Roberts SK

(2022), Hepatol Commun, 6(11), 3260-70

DOI: 10.1002/hep4.2089

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, Prout T, Ameratunga M, Chénard-Poirier M, Curcean A, Bertan C, Baker C, Miranda S, Masrour N, Chen W, Pereira R, Figueiredo I, Morilla R, Jenkins B, Zachariou A, Riisnaes R, Parmar M, Turner A, Carreira S, Yap C, Brown R, Tunariu N, Banerji U, Lopez J, de Bono J, Minchom A

(2022), J Immunother Cancer, 10(6), e004495

DOI: 10.1136/jitc-2022-004495

A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers

Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM

(2022), Invest New Drug, 40(4), 747-55

DOI: 10.1007/s10637-022-01237-3

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study

Dean A, Gill S, McGregor M, Broadbridge V, Järveläinen HA, Price T

(2022), LANCET GASTROENTEROL, 7(10), 943-51

DOI: 10.1016/S2468-1253(22)00167-4

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ

(2022), Clin Cancer Res, 28(12), 2527-35

DOI: 10.1158/1078-0432.CCR-21-4283

Landscape of clinical trials across the pancreatic cancer care continuum: an Australian perspective

Khan NN, Basrai H, Evans SM, Ioannou LJ, Pilgrim CH, Zalcberg JR, Jones GM, Hanson S

(2022), MED J AUSTRALIA, 217(10), 505-9

DOI: 10.5694/mja2.51756

Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer

Chong CY, Jalali A, Wong HL, Loft M, Wong R, Lee M, Gately L, Hong W, Shapiro J, Kosmider S, Tie J, Ananda S, Yeung JM, Ma B, Burge M, Jennens R, Tran B, Lee B, Lim L, Dean A, Nott L, Gibbs P

(2022), ASIA-PAC J CLIN ONCO, 18(5), e363-8

DOI: 10.1111/ajco.13728

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot

Pilgrim CHC, Maciejewska A, Ayres N, Ellis S, Goodwin M, Zalcberg JR, Haydon A

(2022), ANZ J Surg, 92(10), 2565-70

DOI: 10.1111/ans.17999

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N

(2022), Journal of thoracic oncology clinical and research reports, 3(11), 100400

DOI: 10.1016/j.jtocrr.2022.100400

1 2 3 Next